Enzene Biosciences, Pune-based contract development and manufacturing organisation (CDMO) known for its flagship fully-connected continuous manufacturing platform (EnzeneX), has announced the launch of a new Drug Discovery Division.

This further expands the CDMO's breadth of services to the biotech industry and complements its EnzeneX equipped biologics manufacturing site, which will open later this summer in the US.

Enzene is introducing its new discovery arm to provide end-to-end integrated discovery services in response to the rapidly growing industry demands. The discovery offerings will include antibody services (target validation, discovery and engineering), reagent production ranging from custom peptides & proteins to advanced modalities like plasmids, RNA and exosomes, and multi-platforms assays services.

While financial details remain undisclosed, the new Discovery Division will be located at Enzene’s Pune facility, with new state-of-the-art discovery laboratories set to be operational by July and further expansions planned later in the year.

Enzene will open its $50 million New Jersey site this summer, which will also be the first site in the USA with a fully connected continuous manufacturing platform and will be staffed by over 300 personnel. The CDMO has immediately available capacity to produce complex proteins along with standard modalities via both CHO and mammalian cell lines.